Hospira in US-wide recall of product due to contamination

pharmafile | January 25, 2017 | News story | Medical Communications Contamination, Hospira, Pfizer 

Hospira, a company owned by Pfizer, has been forced to recall a batch of injectable drugs due to “the presence of particulate matter within a single vial”. What exactly was found is not clear, but a customer apparently called the matter to Hospira’s attention and it immediately announced a voluntary recall.

The side-effects of anyone using Vancomycin Hydrochloride, an antibiotic to fight bacteria in the intestines, with the particular contamination were announced to be “local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or low-level allergic response to the particulate.” To date, there have been no adverse reactions to the faulty batch of drugs but this has not prevented Hospira from taking action.

It is particularly embarrassing for the company, which was forced to recall anaesthetic in August of last year due, again, to a ‘particulate matter’ being found in a vial of the drug, bupivacaine hydrochloride injection. On this particular occasion, the faulty product was produced at Rocky Mount manufacturing facility, which has been linked to a string of faulty products being launched.

It is not clear whether the current recall is from the same location but a letter has been issued to all customers worldwide to notify them of the dates that the faulty products lie under.

Ben Hargreaves

Related Content

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …

FDA approves Pfizer’s vaccine for the prevention of RSV in children

On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo …

FDA grants accelerated approval to Pfizer’s Elrexfio

Pfizer has that the US Food and Drug Administration (FDA) has granted accelerated approval to …

Latest content